OPRM1 A118G gene variant and postoperative opioid requirement: A systematic review and meta-analysis

Anesthesiology

Volumn 121, Issue 4, 2014, Pages 825-834

  Hwang, In Cheol ^a   Park, Ji Young ^b   Myung, Seung Kwon ^c   Ahn, Hong Yup ^d   Fukuda, Ken Ichi ^e   Liao, Qin ^f  

^a Gachon University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d Dongguk University   (South Korea)

^e TOKYO DENTAL COLLEGE   (Japan)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; OPRM1 PROTEIN, HUMAN;

ANIMAL; GENETIC VARIABILITY; GENETICS; HUMAN; META ANALYSIS; PAIN, POSTOPERATIVE; POSTOPERATIVE CARE; PROCEDURES;

ANALGESICS, OPIOID; ANIMALS; GENETIC VARIATION; HUMANS; PAIN, POSTOPERATIVE; POSTOPERATIVE CARE; RECEPTORS, OPIOID, MU;

EID: 84914154278     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000405     Document Type: Review

References (74)

1. Droney J, Riley J, Ross JR: Evolving knowledge of opioid genetics in cancer pain. Clin Oncol (R Coll Radiol) 2011; 23:418-28.
2. Somogyi AA, Barratt DT, Coller JK: Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-44.
3. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH: Consequences of the 118A>G polymorphism in the OPRM1 gene: Translation from bench to bedside? J Pain Res 2013; 6:331-53.
4. Beyer A, Koch T, Schröder H, Schulz S, Höllt V: Effect of the A118G polymorphism on binding affinity, potency and agonistmediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004; 89:553-60.
5. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ: The single nucleotide polymorphism A118G alters functional properties of the human μ opioid receptor. J Neurochem 2007; 103:77-87.
6. Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G, Schmidt PH, Lötsch J: A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 2009; 284:6530-5.
7. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA: Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A 2009; 106:10847-52.
8. Wang YJ, Huang P, Ung A, Blendy JA, Liu-Chen LY: Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience 2012; 205:178-84.
9. Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W: Allelic expression imbalance of human μ opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280:32618-24.
10. Walter C, Lötsch J: Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146:270-5.
11. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I: How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 2005; 26:311-7.
12. Wu CL, Raja SN: Treatment of acute postoperative pain. Lancet 2011; 377:2215-25.
13. Costantini R, Affaitati G, Fabrizio A, Giamberardino MA: Controlling pain in the post-operative setting. Int J Clin Pharmacol Ther 2011; 49:116-27.
14. Allegri M, De Gregori M, Niebel T, Minella C, Tinelli C, Govoni S, Regazzi M, Braschi A: Pharmacogenetics and postoperative pain: A new approach to improve acute pain management. Minerva Anestesiol 2010; 76:937-44.
15. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. PLoS Med 2009; 6:e1000097.
16. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5:13.
17. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Oxford, The Cochrane Collaboration, 2011.
18. Hardy GH: Mendelian proportions in a mixed population. Science 1908; 28:49-50.
19. Kokki H, Kokki M, Sjövall S: Oxycodone for the treatment of postoperative pain. Expert Opin Pharmacother 2012; 13:1045-58.
20. Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Deleon- Casasola OA, Eilers JG, Ferrell B, Janjan NA, Karver SB, Levy MH, Lynch M, Moryl N, Murphy BA, Nesbit SA, Oakes L, Obbens EA, Paice JA, Rabow MW, Syrjala KL, Urba S, Weinstein SM; NCCN Adult Cancer Pain: Adult cancer pain. J Natl Compr Canc Netw 2010; 8:1046-86.
21. Fukuda K, Hayashida M, Ide S, Saita N, Kokita Y, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Nagashima M, Tagami M, Komatsu H, Sora I, Koga H, Kaneko Y, Ikeda K: Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 2009; 147:194-201.
22. Fukuda K, Hayashida M, Ikeda K, Koukita Y, Ichinohe T, Kaneko Y: Diversity of opioid requirements for postoperative pain control following oral surgery-Is it affected by polymorphism of the μ-opioid receptor? Anesth Prog 2010; 57:145-9.
23. Zhang F, Liao Q, Li L, Wang SY, Hu R, Tang YZ, Ouyang W: The correlation between post-operative fentanyl requirements and μ-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy. Exp Ther Med 2013; 5:1147-52.
24. Lettre G, Lange C, Hirschhorn JN: Genetic model testing and statistical power in population-based association studies of quantitative traits. Genet Epidemiol 2007; 31:358-62.
25. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF Jr, Freimer NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS, Harris EL, Hoh J, Hoover R, Kong CA, Merikangas KR, Morton CC, Palmer LJ, Phimister EG, Rice JP, Roberts J, Rotimi C, Tucker MA, Vogan KJ, Wacholder S, Wijsman EM, Winn DM, Collins FS: Replicating genotypephenotype associations. Nature 2007; 447:655-60.
26. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B: Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105:334-7.
27. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ: Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50:787-92.
28. Zintzaras E: Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur J Epidemiol 2010; 25:553-60.
29. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58.
30. Cohen J: A power primer. Psychol Bull 1992; 112:155-9.
31. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
32. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics 2000; 56:455-63.
33. Zhang W, Chang YZ, Kan QC, Zhang LR, Lu H, Chu QJ, Wang ZY, Li ZS, Zhang J: Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 2010; 65:130-5.
34. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY: Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol 2011; 77:33-9.
35. Zhang S, Li S, Tan X: [Human μ-opioid receptor A118G polymorphism affects epidural patient-controlled analgesia with fentanyl]. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33:309-11.
36. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC: A118G single nucleotide polymorphism of human μ-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109:520-6.
37. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT: Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain 2009; 5:32.
38. Sia AT, Lim Y, Lim EC, Ocampo CE, Lim WY, Cheong P, Tan EC: Influence of mu-opioid receptor variant on morphine use and self-rated pain following abdominal hysterectomy. J Pain 2013; 14:1045-52.
39. Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T, Ruiz-Velasco V, Mets B: A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 2006; 103:1011-7.
40. Henker RA, Lewis A, Dai F, Lariviere WR, Meng L, Gruen GS, Sereika SM, Pape H, Tarkin IS, Gowda I, Conley YP: The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol Res Nurs 2013; 15:309-17.
41. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Trégouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L: Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79:316-24.
42. Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A: Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg 2011; 112:448-53.
43. Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K: Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol 2012; 52:234-42.
44. De Gregori M, Garbin G, De Gregori S, Minella CE, Bugada D, Lisa A, Govoni S, Regazzi M, Allegri M, Ranzani GN: Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharmacol 2013; 69:1651-8.
45. Kim KM, Kim HS, Lim SH, Cheong SH, Choi EJ, Kang H, Choi HR, Jeon JW, Yon JH, Oh M, Shin JG: Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. Int J Clin Pharmacol Ther 2013; 51:383-92.
46. Kindler LL, Sibille KT, Glover TL, Staud R, Riley JL III, Fillingim RB: Drug response profiles to experimental pain are opioid and pain modality specific. J Pain 2011; 12:340-51.
47. Anderson KO, Green CR, Payne R: Racial and ethnic disparities in pain: Causes and consequences of unequal care. J Pain 2009; 10:1187-204.
48. Green CR, Anderson KO, Baker TA, Campbell LC, Decker S, Fillingim RB, Kalauokalani DA, Kaloukalani DA, Lasch KE, Myers C, Tait RC, Todd KH, Vallerand AH: The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med 2003; 4:277-94.
49. Hastie BA, Riley JL III, Kaplan L, Herrera DG, Campbell CM, Virtusio K, Mogil JS, Wallace MR, Fillingim RB: Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity. Pain 2012; 153:1610-9.
50. Tan EC, Lim Y, Teo YY, Goh R, Law HY, Sia AT: Ethnic differences in pain perception and patient-controlled analgesia usage for postoperative pain. J Pain 2008; 9:849-55.
51. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR: Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPAaxis activation. Pharmacogenet Genomics 2007; 17:1031-8.
52. Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Komatsu H, Sora I, Fukuda K, Koga H, Hanaoka K, Ikeda K: Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008; 9:1605-16.
53. Levran O, Awolesi O, Linzy S, Adelson M, Kreek MJ: Haplotype block structure of the genomic region of the μ opioid receptor gene. J Hum Genet 2011; 56:147-55.
54. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL: MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-21.
55. Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A: Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 2006; 39:303-8.
56. Bernard S, Neville KA, Nguyen AT, Flockhart DA: Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006; 11:126-35.
57. Chen YT, Tsou HH, Kuo HW, Fang CP, Wang SC, Ho IK, Chang YS, Chen CH, Hsiao CF, Wu HY, Lin KM, Chen ACh, Tsai-Wu JJ, Liu YL: OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: A cross sectional study. J Hum Genet 2013; 58:84-90.
58. Zheng H, Zou H, Liu X, Chu J, Zhou Y, Loh HH, Law PY: Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans. J Lipid Res 2012; 53:1153-62.
59. Raehal KM, Schmid CL, Groer CE, Bohn LM: Functional selectivity at the μ-opioid receptor: Implications for understanding opioid analgesia and tolerance. Pharmacol Rev 2011; 63:1001-19.
60. 2+ channels in humanized mouse sensory neurons. Anesthesiology 2011; 115:1054-62.
61. Pasternak GW: Preclinical pharmacology and opioid combinations. Pain Med 2012; 13(suppl 1):S4-11.
62. Smith HS: Variations in opioid responsiveness. Pain Physician 2008; 11:237-48.
63. Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM: A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006; 123:28-36.
64. De Schepper HU, Cremonini F, Park MI, Camilleri M: Opioids and the gut: Pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16:383-94.
65. Aziz Q, Botha C, Willert R: Pharmacology of visceral pain: Central factors. Dig Dis 2009; 27(suppl 1):31-41.
66. Cervero F: Visceral versus somatic pain: Similarities and differences. Dig Dis 2009; 27(suppl 1):3-10.
67. Ness TJ, Gebhart GF: Visceral pain: A review of experimental studies. Pain 1990; 41:167-234.
68. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B: Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology 2003; 98:1415-21.
69. Spencer CC, Su Z, Donnelly P, Marchini J: Designing genome-wide association studies: Sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 2009; 5:e1000477.
70. Edwards RR, Fillingim RB, Ness TJ: Age-related differences in endogenous pain modulation: A comparison of diffuse noxious inhibitory controls in healthy older and younger adults. Pain 2003; 101:155-65.
71. Fillingim RB, Gear RW: Sex differences in opioid analgesia: Clinical and experimental findings. Eur J Pain 2004; 8:413-25.
72. Gear RW, Miaskowski C, Heller PH, Paul SM, Gordon NC, Levine JD: Benzodiazepine mediated antagonism of opioid analgesia. Pain 1997; 71:25-9.
73. Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N: Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphinerelated side-effects after major surgery: A systematic review. Br J Anaesth 2011; 106:292-7.
74. Oertel BG, Doehring A, Roskam B, Kettner M, Hackmann N, Ferreirós N, Schmidt PH, Lötsch J: Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet 2012; 21:4751-60.